Literature DB >> 8960121

A CD30 responsive element in the germline epsilon promoter that is distinct from and inhibitory to the CD40 response element.

M D Jumper1, K Fujita, P E Lipsky, K Meek.   

Abstract

Germline epsilon (I epsilon) transcription is requisite for IgE switch recombination. I epsilon transcription is markedly increased by ligation of CD40 and/or by IL-4 stimulation. By contrast, we found previously that stimulation through CD30 inhibits I epsilon transcription in EBV-transformed B cell lines. To characterize the molecular mechanisms involved in these contradictory events, the promoter elements that are responsible for I epsilon transcriptional regulation were determined using stable CAT reporter gene constructs. The results define a 95 bp CD30 responsive element (CD30RE) located 5' of the previously defined CD40 responsive element (CD40RE) that resides within the same 95 bp fragment as the IL-4RE and ablates CD40L induced I epsilon promoter activity. However, IL-4 overrides the inhibitory effect of CD30L. These results define a CD30RE and provide further evidence for the complex regulation of I epsilon transcription by various members of the CD40L/TNF alpha family of molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960121     DOI: 10.1016/s0161-5890(96)00045-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  2 in total

1.  CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells.

Authors:  A Cerutti; A Schaffer; S Shah; H Zan; H C Liou; R G Goodwin; P Casali
Journal:  Immunity       Date:  1998-08       Impact factor: 31.745

Review 2.  AID to overcome the limitations of genomic information by introducing somatic DNA alterations.

Authors:  Tasuku Honjo; Masamichi Muramatsu; Hitoshi Nagaoka; Kazuo Kinoshita; Reiko Shinkura
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2006-05       Impact factor: 3.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.